Methods: We selected 12 subjects who died of severe infections with aplastic thymus found on autopsy, and 11 control subjects who died of unrelated causes, such as congenital heart disease. The presence of several markers, including Bcl2, P53, lymphocytic markers, and CD68, was examined using immunohistochemical methods on paraffin-embedded thymus sections. Positively-stained cells were counted per 1000 cells and the results stated as percentage of positive cells.
Results: The mean age of the control group was between 7 days to 18 months (mean: 4.5 months). Parental consanguinity was present in 45.5% and 9.1% of the control and case groups, respectively however, this was not statistically significant. We found significantly lower expression of Bcl2 in the case group (p value: 0.038). Furthermore, expression of CD68 was significantly higher in the case group. Epithelial markers were significantly higher in case subjects, although CD8 expression was higher in the control group. The presence of other markers was not significantly different between the two groups.
Conclusions: Increase in apoptosis has a role in aplastic thymuses and prevention of apoptosis may halt this process. Also high CD68 expression denotes increased phagocytic activity in aplastic thymuses.Background: The postmortem diagnosis of early myocardial infarction is a perplexing affair in forensic pathology. The routine evaluations of autopsied hearts including macroscopic examination and study of H&E stained sections are often not contributory. Some other methods like electron microscopy need sophisticated equipments which are not available in all pathology laboratories.
Methods: In an attempt to find a more reliable and less labor- intensive method, we have studied the diagnostic value of cardiac troponin- T by an optimized immunohistochemical method on 67 autopsied hearts in Legal Medicine Organization of Iran. The cases were divided into three groups: the positive group composed of cases with the definite diagnosis of myocardial infarction (MI) as the cause of death the non-cardiac death group and finally the suspicious group which consisted of cases with high probability of early myocardial infarction, however without definite evidence of MI on the routine histopathologic studies. In stained sections, the degree of troponin T depletion was scored.
Results: With our proposed cut off, this test showed positive results in 19 out of 22 cases in MI group (86.4%), none of the 17 cases of non-cardiac death (100% specificity), and 15 out of 28 cases of suspicious group (53.6%).
Conclusions: This relatively easy method may increase the sensitivity of routine histopathologic methods in postmortem detection of early myocardial infarction. Additionally, this method does not require a particular preparation and can be done very easily on the archival paraffin blocks available in pathology departments whenever further evaluation is deemed necessary by the pathologist.
Normal
0
false
false
false
EN-US
X-NONE
AR-SA
MicrosoftInternetExplorer4
Background: Diffuse large B Cell lymphoma (DLBCL)
is the most common subtype of non-Hogkin lymphoma (NHL).
We performed a retrospective study of patients with de novo DLBCL
treated in the Medical Oncology department of Cancer Institute of Iran, Tehran
to assess the clinicopathologic and immunohistochemistry correlation and
prognosis of the patients.
Methods: World Health Organization
(WHO) classification was used to reexamine 1470
biopsy specimens related to the years 1985-2006.
After excluding five cases of T Cell
large cell lymphoma, 50 Patients diagnosed as
DLBCL.
Results: Median age of the patients was 45.5(20-85)
years: 60% were male and 30%
had primary extranodal disease. The most common extranodal sites were bone,
gastrointestinal tract and Head and neck areas. The most common stages were
stage II (32%), stage III (32%),
stage IV (20%) and stage I
(16%) retrospectively and 33% had B-symptoms.
All of The Patients received chemotherapy (83% CHOP regimen)
and 46% treated by radiotherapy after chemotherapy. With
a mean follow up time of 32 months, median
survival time was 34 (95% CI 24-40) months.
Prognostic factors for survival were tumor stage, B-symptoms
and early relapse (less than 6 months).
Conclusions: Our data showed the importance of Immunohistochemistry method in diagnosis of DLBCL.
Although DLBCL is potentially curable
with CHOP chemotherapy protocol, addition of monoclonal
antibody (Anti CD20) and finding new
prognostic factors to predict early relapse are clearly needed in Iran.
Normal
0
false
false
false
EN-US
X-NONE
AR-SA
MicrosoftInternetExplorer4
Background: Uterine smooth muscle tumors classified as
leiomyoma, leiomyosarcoma and tumors with uncertain malignant potential. The
leiomyoma and leiomyosarcoma are separated tumors biologically. Uterine smooth
muscle tumors with uncertain malignant potential include a group of tumors
which are not specifically placed into two others groups which result in a
serious problem in a way of their treatment. In the present study expression of
marker "p16"
in smooth muscle tumors of uterine and normal
myometrium
has been investigated.
Methods: The
entire paraffin blocks related to hysterectomy cases with diagnosis of normal
myometrium, leiomyoma and leiomyosarcoma (3768 cases) available in pathology lab. in Shariati
Hospital in Tehran, Iran from 1372 to 1387 were investigated. Among them 62 normal
myometrium, 62 leiomyoma and 12 leiomyosarcoma had been chosen and after staining for
marker "p16" were investigated
separately.
Results: There were
a statistically significant difference in both intensity and percentage of
staining for this marker between leiomyoma and leiomiosarcoma (p< 0.001) and between
leiomyosarcoma and normal myometrium (p< 0.001) but not
between leiomyoma and normal myometrium (p= 3.6).
Conclusion: Based on this study
if strong and more than focal immunoreactivity for marker "p16" suppose as positive
then leiomyosarcoma will be positive for this marker but leiomyoma and normal
myometrium will not be and this could be considered as a good guide for
categorizing the uterine smooth muscle tumors.
Normal
0
false
false
false
EN-US
X-NONE
AR-SA
MicrosoftInternetExplorer4
Background: Cyclooxygenase 2 is a key enzyme which converts arachidonic acid into
prostaglandins. Cyclooxygenase 2 is triggered by
inflammatory stimuli, such as cytokines. Its expression increases in tumors and
Alzheimer's disease and ovarian hyperstimulation syndrome. Polycystic ovarian
syndrome is a heterogeneous disease characterized by pathological angiogenesis
and chronic anovulation. In the present study, the probable role of
cyclooxygenase 2 in Wistar rats with polycystic
ovarian syndrome was investigated.
Methods: Thirty
female Wistar rats (170-200 gr)
were equally divided into three groups: 2 mg
estradiol valerate was intramuscularly administered to each rat in the
experiment group or group 1 the rats in group 2 were regarded as the sham group and received sesame oil
injections and group 3 or the control group received no
injections. After 60 days of treatment, animals were
anaesthetized with chloroform and killed by decapitation. Ovaries were
collected for histological and immunohistochemical evaluations. All the
experiments were repeated three times.
Results: Morphologically, ovaries from the
control group exhibited follicles in various stages of development and many
fresh corpus luteum. In estradiol valerate group small follicles in early
development were observed in addition to follicles showing evidence of atresia
and many large cysts with thickened theca cell layer. Corpus luteum was rare or
absent in group 2. The immunohistochemical analysis
for cyclooxygenase 2 expression showed an increased
expression of cyclooxygenase 2 enzyme in group 1.
Conclusion: The results suggested the involvement of
cyclooxygenase 2 in
the progression to polycystic ovarian syndrome in a rat model.
Background: Endometrial carcinoma (EC) is the most common gynecologic malignancy however, mechanisms underlying its pathogenesis remain obscure. Endometrial carcinoma has been classified into two major categories: type I (related to estrogen or endometrioid adenocarcinoma) and type II (unrelated to estrogen). Estrogen is the main trigger for the abnormal proliferation in the endometrial epithelium but progesterone can inhibit this process. The aim of this study was to analyze the expression of estrogen and progesterone receptors in all types of endometrial hyperplasia in comparison to endometrioid adenocarcinoma of endometrium.
Methods: Forty-seven specimens including 23 cases of histopathologically confirmed hyperplastic endometrium (12 simple hyperplasia, 5 complex hyperplasia without atypia, and 6 complex hyperplasia with atypia) and 24 cases of endometrial carcinoma were studied. Immunohistochemical staining of estrogen and progesterone receptors was performed in paraffin-embedded blocks and expression of estrogen and progesterone receptors were scored according to the proportion of positive staining cells.
Results: Overexpression of progesterone receptors was seen in 18 (75%) out of 24 cases of endometrial carcinoma and 23 (100%) of all types of endometrial hyperplasia. The aforesaid differences were statistically significant (P=0.023). 70.8% of cases with endometrial carcinoma were 3+ for immunohistochemical staining of progesterone receptors as were 85.7% of the cases with endometrial hyperplasia the difference being also statistically significant (P=0.02).
Conclusion: Considering the increased proportion of progesterone receptor expression in all types of hyperplastic endometrium in comparison to endometrial carcinoma, hormonal therapy by progestinal agents is recommended as a treatment of choice.
Background: Transitional Cell Carcinoma (TCC) is the most common type of urinary bladder cancer. Cyclooxygenase-2 (COX-2), a key enzyme in prostaglandins biosynthesis, has been introduced as a new candidate for targeted therapy in this cancer. In this study, we investigated the expression of COX-2 in urinary bladder TCCs and its relationship with clinicopathological parameters such as tumor grade and stage.
Methods: This cross-sectional study was performed in the Pathology department of Sina Hospital in Tehran, Iran during 2006-2011. Pathology reports of patients with definite diagnosis of urinary bladder TCCs who had undergone Transurethral Resection (TUR) were reviewed and 40 cases were selected. Subsequently, COX-2 expression was assessed immunohistochemically by the examination of paraffin embedded tissue blocks. Staining in more than 5% of tumor cells was considered as positive expression.
Results: COX-2 was expressed in 52.5% of the patients. High-grade tumors revealed a higher (87.5%) COX-2 expression versus other grades of the lesions and there was a statistically significant difference in COX-2 expression between them (P<0.001). Patients' age was also related to the expression of this marker (P=0.03). In contrast, this marker did not correlate with other characteristics including gender, lymphatic invasion or tumor stage. In addition, perineurial or vascular invasions were not detected in any of the patients.
Conclusion: COX-2 expression was seen in more than half of our patients and it had a marked relation to tumor differentiation. Accordingly, this molecule may be a useful tumor marker in the assessment of urinary bladder cancers.
Background: Breast cancer is the most common cancer in women around the world. It has been known for over a century that androgens and androgen receptor (AR) play a role in normal and neoplastic breast cells. The aim of this study was to determined the AR expression on tumor cells and its correlation with other prognostic and predictive factors as well as contribution of AR in patients overall survival (OS) and disease- free survival (DFS). Methods: This retrospective cross-sectional study performed on 189 patients who referred to Medical Oncology Ward of Cancer Institute, Tehran University of Medical Sciences, from April 2007 to February 2010. We performed an immunohistochemistry study for AR (AR441 clone, Dako, Germany) (10% cut-off point) and Ki-67 MIB-1 clone, Dako, Germany) on paraffin embedded blocks. Other data were extracted from patients’ documents. Results: Overall, AR expression was 49.1%. Mean age of the patients with and without AR was 47.86 and 48.49 years, respectively. AR positive tumors presented more in stage I/II than III/IV (P=0.02) and AR were more positive for estrogen receptor positive, lower grade of tumor (grade I/II versus III) and lower Ki-67 (P=0.01). AR positivity had neither correlation with progesterone receptor, HER2/neu, P53 expression or menopausal status. OS and DFS were higher in AR positive patients but did not reach statistical significance. In triple-negative breast cancer (TNBC) group, 25% of tumors showed AR expression. AR had non-significant positive correlation with OS in TNBC cancer patients. OS and DFS had significant statistic positive correlation with ER, PR and stage regardless of AR status. Conclusion: Based on this study, although androgen receptor expression showed correlation with other prognostic factors for survival in patients, we didn’t find statistically significant independent relationship between AR and overall survival in patients. As far as there isn’t any targeted therapy for triple-negative breast cancer (TNBC), prospective basic and clinical studies regarding AR inhibitors in the treatment of TNBC seems to be logical and valuable.
Page 1 from 1 |
© 2025 , Tehran University of Medical Sciences, CC BY-NC 4.0
Designed & Developed by : Yektaweb